Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update

(2022) Ningyuan Wen et al.   BioScience Trends

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma

(2022) Zijian Yang et al.   Cancers

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

(2022) Takuya Sho et al.   Cancers

Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data

(2022) Shigeo Shimose et al.   HEPATOLOGY RESEARCH

Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

(2022) Shunichi Hosoda et al.   Liver Cancer

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

(2022) M. Rimini et al.   ESMO Open

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

(2021) Masatoshi Kudo et al.   JOURNAL OF GASTROENTEROLOGY

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria

(2021) Takuya Sho et al.   HEPATOLOGY RESEARCH

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

(2021) Toshiki Iwai et al.   Scientific Reports

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI

(2021) Akinori Kubo et al.   Cancers

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumors

(2021) Nobuyuki Ishikura et al.   ONCOLOGY REPORTS

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct Characteristics of VEGF‐D and VEGF‐C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease

(2020) Hiromichi Wada et al.   Journal of the American Heart Association

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

(2020) Masatoshi Kudo et al.   Liver Cancer

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

(2020) John D. Gordan et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

(2019) Abhishek S. Kashyap et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Epidemiology and Management of Hepatocellular Carcinoma

(2018) Laura Kulik et al.   GASTROENTEROLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

(2017) Priti S. Hegde et al.   SEMINARS IN CANCER BIOLOGY

Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D

(2016) Natalia Davydova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

(2016) Goki Suda et al.   JOURNAL OF GASTROENTEROLOGY

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

(2015) A. Scholz et al.   EMBO Molecular Medicine

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE